COMPASS Reaffirms Q4 2026 NDA Completion and H1 2027 Launch, But Adds No New Launch Mechanics

What happened

Compass Pathways used the Morgan Stanley conference to repeat its existing timeline: complete the rolling NDA for COMP360 in Q4 2026 and launch in the US in H1 2027. That message matches the company's prior disclosures and does not resolve the open questions around DEA rescheduling, REMS architecture, or site readiness. The stock already trades at a $1.59 billion market cap with no revenue and $162.6 million net loss in the first half of 2026, implying much of the clean regulatory path is priced in. The DeepValue master report rates the name a WAIT with an attractive entry near $10 and suggests trimming above $15, because the next six to nine months depend on controlled-substance logistics rather than further clinical success. Without concrete launch-readiness disclosures, today's comments are more affirmation than de-risking.

Implication

Investors should continue to monitor for observable progress on REMS, distributor setup, and site certification. The current price offers limited margin of safety, and any delay in filing or scheduling could compress the premium quickly. A better risk-reward profile emerges closer to $10, where the cash runway into 2028 provides more downside protection. Conversely, tangible evidence of accelerated FDA review under the priority voucher would support a higher valuation. Until those milestones are disclosed, the stock is a hold for existing positions and not a new buy.

Thesis delta

The thesis remains unchanged: COMPASS is a late-stage regulatory and launch story with first-mover advantage but unproven commercialization. The news confirms management's timeline but adds no new evidence on launch mechanics. The WAIT rating and $10-$15 range remain appropriate.